ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bind nanomedicine assets may go to Pfizer

by Ann M. Thayer
July 11, 2016 | APPEARED IN VOLUME 94, ISSUE 28

Bind Therapeutics, which filed for bankruptcy in May, has signed a preliminary agreement to sell most of its assets to Pfizer for close to $20 million. If the company receives a higher bid by July 22, it will auction its assets. If Pfizer’s offer is selected as the highest, or no better bids come in, Bind expects to complete the sale, subject to court approval, in the third quarter. Bind and Pfizer became collaborators through a multi-million-dollar deal in April 2013.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment